ITGA2 and neoplasm: In this study, we found that ITGA2 inhibition increased the ratio of tumor-killing lymphocytes and decreased the proportion of immunosuppression-related cells in tumors (Fig. 7), which suggests that ITGA2 might be an ideal candidate for immune therapy.